DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Postpartum Depression, historical and forecasted epidemiology, as well as the Postpartum Depression Market Trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover more about the epilepsy market in detail @ Postpartum Depression Market Report
Key Takeaways from the Postpartum Depression Market Report
- In February 2026, the last patient completed the final study visit in a confirmatory Phase III trial evaluating LPCN 1154 for PPD, with topline results expected in early April 2026.
- In January 2026, Reunion Neuroscience reported full data from the RECONNECT Phase II clinical trial of RE104 for the treatment of PPD at the ACNP Annual Meeting.
- In January 2026, Lipocine reported completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase III trial of LPCN 1154 for PPD, with the study recommended to continue without modification.
- In 2025, the total diagnosed prevalent cases of maternal PPD in the 7MM were approximately 1.3 million, and this number is expected to rise during the forecast period, driven by increased awareness, improved screening and diagnosis, as well as factors such as pandemic-related stress, economic pressures, and reduced social support.
- Among the 7MM, the US accounted for the largest share of diagnosed prevalent cases of maternal PPD in 2025, with approximately 700,000 cases, reflecting higher awareness, robust screening practices, and greater access to maternal mental healthcare services.
- In the seven major Postpartum Depression Therapeutics Market, SNRI’s and SSRI’s constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023.
- In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2036.
- Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market.
- Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023
- Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2036.
- The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
- Promising Postpartum Depression Therapies such as SAGE-217, Brexanolone, MI078, RE104, SAGE-547, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, LPCN 1154A and others.
Get a Free sample for the Postpartum Depression Market Report @ Postpartum Depression Therapeutics Market
Postpartum Depression Overview
Postpartum Depression is a type of mood disorder that can affect women after giving birth. It goes beyond the common “baby blues” and involves persistent feelings of sadness, anxiety, and exhaustion that can interfere with a mother’s ability to care for herself and her baby. PPD typically develops within the first few weeks after delivery but can appear anytime within the first year postpartum. Postpartum depression is a serious but treatable condition. Early recognition and proper support—through therapy, medication, or counseling—can significantly improve outcomes for both the mother and the child.
Postpartum Depression Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Population of Maternal Postpartum Depression
Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence
Postpartum Depressions Marketed Therapies
- ZURZUVAE (zuranolone): Sage Therapeutics/Biogen
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
- ZULRESSO: Sage Therapeutics
ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits.
Emerging Bipolar Depression Drugs
- Luvesilocin (RE104): Reunion Neuroscience
Luvesilocin is an investigational therapy being evaluated for PPD, currently in Phase II clinical development, designed to modulate neuroactive pathways involved in mood regulation. It is expected to initiate a pivotal Phase III clinical trial in 2026, with the aim of improving depressive symptoms and restoring emotional and functional balance in affected individuals.
- NORA520: TWi Biotechnology
NORA520 is an investigational therapy being evaluated for adults with PPD, currently in Phase II clinical development. It is designed to target neurobiological pathways involved in mood regulation, aiming to improve depressive symptoms and overall functional outcomes in affected individuals.
- LPCN 1154: Lipocine
BRLIZIO (LPCN 1154) is an investigational oral therapy being evaluated for adults with PPD, currently in late-stage clinical development. It is designed to modulate neuroactive hormonal pathways involved in mood regulation, with a new drug application (NDA) submission in the US expected in mid-2026.
Discover more about therapies set to grab major Postpartum Depression Market Share @ Postpartum Depression Market Drivers and Barriers
Postpartum Depressions Market Outlook
Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.
Postpartum Depressions Disease Treatment Landscape
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.
Get exclusive access to detailed forecasts, Postpartum Depression Market Dynamics, and competitive intelligence by requesting the full report @ Postpartum Depression Market Access and Reimbursement
Scope of the Postpartum Depression Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
- Postpartum Depression Therapies- SAGE-217, Brexanolone, MI078, RE104, SAGE-547, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, LPCN 1154A and others.
- Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression Emerging Therapies
- Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Postpartum Depression Market Barriers
- Postpartum Depression Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement
To know more about Postpartum Depression Companies working in the treatment market, visit @ Postpartum Depression Market Ongoing Clinical Trials Assessment
Table of Contents
- Key Insights
- Postpartum Depression Market Report Introduction
- Postpartum Depression Market Overview at a Glance
- Methodology of Postpartum Depression Epidemiology and Market
- Executive Summary
- Key Events
- Disease Background and Overview
- Postpartum Depression Patient Journey
- Postpartum Depression Epidemiology and Patient Population
- Postpartum Depression Marketed Drugs
- Postpartum Depression Emerging Drugs
- Postpartum Depression: Market Analysis
- Key Opinion Leaders’ Views
- Postpartum Depression SWOT Analysis
- Postpartum Depression Unmet Needs
- Postpartum Depression Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.5
